The new guidelines from the British Association for Psychopharmacology for anxiety disorders

References

• Baldwin DS, Anderson IM, Nutt DJ, et al. British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005; 19: 567–96
   PubMed Web of Science ®Google Scholar
• Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ. WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders. World J Biol Psychiatry 2002; 3: 171–99
   PubMedGoogle Scholar
• NICE. Anxiety: management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. 2004; Dec:reference CG022.
   Google Scholar
• NICE. Obsessive Compulsive Disorder: Core interventions in the treatment of obsessive compulsive disorder and body dysmorphic disorder. 2005; Nov:reference CG031.
   Google Scholar
• NICE. Anxiety: Management of post-traumatic stress disorder in adults in primary, secondary and community care. 2005; Mar:reference CG026.
   Google Scholar
• Lieb R, Becker E, Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol 2005; 15: 445–52
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe-a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 2005; 15: 357–76
   PubMed Web of Science ®Google Scholar
• Grant BF, Hasin DS, Stinson FS, et al. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med 2005b; 35: 1747–59
   PubMed Web of Science ®Google Scholar
• Grant BF, Hasin DS, Blanco C, et al. The epidemiology of social anxiety disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2005; 66: 1351–61
   PubMed Web of Science ®Google Scholar
• Ronalds C, Creed F, Stone K, Webb S, Tomenson B. Outcome of anxiety and depressive disorders in primary care. Br J Psychiatry 1997; 171: 427–33
   PubMed Web of Science ®Google Scholar
• Ormel J, Koeter MW, van den Brink W, van de Willige G. Recognition, management, and course of anxiety and depression in general practice. Arch Gen Psychiatry 1991; 48: 700–6
   PubMed Web of Science ®Google Scholar
• Yonkers KA, Dyck IR, Warshaw M, Keller MB. Factors predicting the clinical course of generalised anxiety disorder. Br J Psychiatry 2000; 176: 544–9
   PubMed Web of Science ®Google Scholar
• Durham RC, Chambers JA, Power KG, et al. Long-term outcome of cognitive behavior therapy clinical trials in central Scotland. Health Technol Assess 2005; 9: 1–174
   PubMed Web of Science ®Google Scholar
• Wang PS, Berglund P, Olfson M, Pincus HA, Wells KB, Kessler RC. Failure and delay in initial treatment contact after first onset of mental disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 603–13
   PubMed Web of Science ®Google Scholar
• Wang PS, Berglund P, Olfson M, Pincus HA, Wells KB, Kessler RC. Failure and delay in initial treatment contact after first onset of mental disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 603–13
   PubMed Web of Science ®Google Scholar
• Giner L, Nichols CM, Zalsman G, Oquendo MA. Selective serotonin reuptake inhibitors and the risk for suicidality in adolescents: An update. Int J Adolesc Med Health 2005; 17(3)211–20
   Google Scholar
• Lenzer J. Manufacturer admits increase in suicidal behavior in patients taking paroxetine. Br Med J 2006; 332(7551)1175
   Google Scholar
• Mitte K. Meta-analysis of cognitive-behavioral treatments for generalized anxiety disorder: a comparison with pharmacotherapy. Psychol Bull 2005; 131: 785–95
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Huusom AKT, Mæhlum E. Escitalopram and paroxetine in the treatment of generalized anxiety disorder. Randomised, placebo-controlled, double-blind study. Br J Psychiatry 2006;189:264–72.
   PubMed Web of Science ®Google Scholar
• Schmitt R, Gazalle FK, Lima MS, Cunha A, Souza J, Kapczinski F. The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta-analysis. Rev Bras Psiquiatr 2005; 27(1)18–24
   Google Scholar
• Davidson JR. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 2001; 62(Suppl 11)46–50
   PubMedGoogle Scholar
• Allgulander C, Florea I, Huusom AK. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 2005;9: doi: 10.1017/S1461145705005973
   Google Scholar
• Mitte K. A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. J Affect Disord 2005; 88: 27–45
   PubMed Web of Science ®Google Scholar
• Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998; 155: 36–42
   PubMed Web of Science ®Google Scholar
• Allgulander C, Mangano R, Zhang J, Dahl AA, Lepola U, Sjodin I, et al. SAD 388 Study Group. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 2004; 19: 387–96
   PubMed Web of Science ®Google Scholar
• Lader M, Stender K, Burger V, Nil R. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 2004; 19: 241–8
   PubMed Web of Science ®Google Scholar